Description:LY2940680 is a small molecule inhibitor primarily known for its role in targeting specific signaling pathways, particularly those involving the phosphoinositide 3-kinase (PI3K) pathway. This compound has garnered attention in the field of cancer research due to its potential therapeutic applications in various malignancies. Characteristically, LY2940680 exhibits high selectivity for certain isoforms of PI3K, which is crucial for minimizing off-target effects and enhancing its efficacy in clinical settings. The compound is typically administered in a research context, and its pharmacological profile includes properties such as oral bioavailability and a favorable half-life, which are essential for effective dosing regimens. Additionally, LY2940680 has been studied for its effects on cellular proliferation, survival, and apoptosis, making it a valuable tool in understanding the molecular mechanisms underlying tumor growth and resistance to therapy. Ongoing research continues to explore its potential in combination therapies and its impact on various cancer types, contributing to the broader landscape of targeted cancer treatments.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![Benzamide, 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(…](https://static.cymitquimica.com/products/IN/thumb/DA000OX0.jpg)
